| Literature DB >> 29510325 |
Natalia C Drosu1, Elazer R Edelman2, David E Housman3.
Abstract
We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved significant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improvements in lesion burden detected by MRI. All improvements have been sustained for more than three years. This response may be related to the action of zidovudine as a known inhibitor of EBV lytic DNA replication, suggesting future directions for clinical investigation.Entities:
Keywords: Epstein-Barr virus; Multiple sclerosis
Mesh:
Substances:
Year: 2018 PMID: 29510325 PMCID: PMC6100748 DOI: 10.1016/j.msard.2018.02.029
Source DB: PubMed Journal: Mult Scler Relat Disord ISSN: 2211-0348 Impact factor: 4.339